Galena Biopharma (NASDAQ:GALE) posted its quarterly earnings results on Monday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.37, American Banking & Market News reports. The company had revenue of $1.32 million for the quarter, compared to the consensus estimate of $1.84 million. Galena Biopharma Inc (NASDAQ:GALE) shares after opening at $3.55 moved to $3.35 on last trade day and at the end of the day closed at $3.22. Company price to sales ratio in past twelve months was calculated as 234.31 and price to cash ratio as 5.19. Galena Biopharma Inc (NASDAQ:GALE) showed a negative weekly performance of -8.52%.
Geron Corporation (NASDAQ:GERN) a biotechnology company received a major setback when it was informed by U.S. Food and Drug Administration (FDA) to suspend its clinical trail on its drug imetelstat for treating Myelofibrosis(a disorder of the bone marrow.) FDA quoted a potential risk to the liver due to long term exposure of the drug. Geron Corporation (NASDAQ:GERN) shares fell -2.73% in last trading session and ended the day on $1.78. GERN return on equity ratio is recorded as -61.60% and its return on assets is -55.40%. Geron Corporation (NASDAQ:GERN) yearly performance is 57.52%.
Inovio Pharmaceuticals Inc (NYSEMKT:INO), a well-known manufacturer of synthetic vaccines needs money to run its various projects and it has announced a way to attain that objective. The biotech company has agreed to dilute its shares with secondary underwritten public offering of a few million common stock shares, rather than go for debts. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares moved down -2.29% in last trading session and was closed at $3.42, while trading in range of $3.37-$3.60. Inovio Pharmaceuticals Inc (NYSEMKT:INO) year to date performance is 17.93%.
The Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) on Feb. 25 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Net loss for the fourth quarter ended December 31, 2013 was $74.2 million, or $0.40 per share, compared to a net loss of $60.5 million, or $0.36 per share, for the same period in 2012. Net loss for the full year 2013 was $274.2 million, or $1.49 per share, compared to a net loss of $220.9 million, or $1.34 per share, for the full year 2012. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is 1.67%. On last trading day company shares ended up $7.91. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average is 1.93%. Analysts mean target price for the company is $8.56.
Leave a Reply